UMB Bank n.a. reduced its holdings in Novo Nordisk A/S (NYSE:NVO – Get Rating) by 1.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,385 shares of the company’s stock after selling 410 shares during the period. UMB Bank n.a.’s holdings in Novo Nordisk A/S were worth $3,165,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Worth Asset Management LLC purchased a new stake in Novo Nordisk A/S in the 1st quarter worth about $32,000. Financial Management Professionals Inc. lifted its stake in Novo Nordisk A/S by 95.0% in the 3rd quarter. Financial Management Professionals Inc. now owns 312 shares of the company’s stock worth $31,000 after acquiring an additional 152 shares in the last quarter. MinichMacGregor Wealth Management LLC purchased a new stake in Novo Nordisk A/S in the 4th quarter worth about $48,000. Penserra Capital Management LLC purchased a new stake in Novo Nordisk A/S in the 3rd quarter worth about $36,000. Finally, Laffer Tengler Investments acquired a new stake in Novo Nordisk A/S in the 3rd quarter valued at approximately $37,000. 6.09% of the stock is owned by hedge funds and other institutional investors.
Novo Nordisk A/S Price Performance
Novo Nordisk A/S stock opened at $139.44 on Friday. The company has a debt-to-equity ratio of 0.29, a current ratio of 0.89 and a quick ratio of 0.69. The company has a market capitalization of $315.55 billion, a PE ratio of 40.18, a price-to-earnings-growth ratio of 1.47 and a beta of 0.47. Novo Nordisk A/S has a one year low of $95.02 and a one year high of $145.94. The business has a 50 day simple moving average of $139.97 and a 200 day simple moving average of $123.57.
Novo Nordisk A/S Increases Dividend
Analyst Upgrades and Downgrades
A number of analysts have issued reports on the company. StockNews.com assumed coverage on Novo Nordisk A/S in a report on Thursday. They issued a “strong-buy” rating on the stock. JPMorgan Chase & Co. raised their target price on Novo Nordisk A/S from 925.00 to 1,100.00 and gave the company an “overweight” rating in a report on Tuesday, January 3rd. Cowen raised their price objective on Novo Nordisk A/S from $130.00 to $145.00 in a research report on Monday, December 12th. Finally, Cowen raised their price objective on Novo Nordisk A/S from $130.00 to $145.00 in a research report on Monday, December 12th. One analyst has rated the stock with a sell rating, four have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $697.78.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases.
- Get a free copy of the StockNews.com research report on Novo Nordisk A/S (NVO)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Get Rating).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.